Abstract:Background Immunotherapy with immune checkpoint inhibitors (ICIs) for solid tumors had significantly improved overall survival. This type of therapy has not been evaluated well in acute myeloid leukemia (AML), and basic information on immune checkpoint (IC) expression levels for comprehensively evaluating the prognosis of patients with AML is lacking. Methods The prognostic value of ICs in AML patients was explored by using RNA-seq and mutant data of 176 AML patients from the Cancer Genome Atlas (TCGA) database and further validated the finding using bone marrow (BM) samples from 62 patients with de novo AML from our department by quantitative real-time PCR. Results Both TCGA data and validation results indicated that high expression of PD-1, PD-L1, and PD-L2 was associated with poor overall survival (OS) in AML patients. In addition, increased co-expression of PD-1 and CTLA-4 (3-year OS: 30% vs 0% (TGCA data), 57% vs 31% (validation group), respectively) or PD-L2 and CTLA-4 (3-year OS: 20% vs 0% (TGCA data), 57% vs 33% (validation group), respectively) correlated with poor AML OS (P < 0.05). Moreover, co-expression of PD-1/PD-L1, PD-1/PD-L1/PD-L2, and PD-1/LAG-3 correlated with poor OS in AML patients with FLT3mut, RUNX1mut, and TET2mut, respectively (P < 0.05). Conclusions High expression of ICs in the BM leukemia cells of AML patients correlated with poor OS. Co-expressions of PD-1/CTLA-4, PD-L2/CTLA-4, PD-1/PD-L1, PD-1/PD-L1/PD-L2, and PD-1/LAG-3 might be used as novel immune predictors for patient OS in AML, and might guide the best choice for precision immune checkpoint blockade in the future. Immunotherapy with immune checkpoint inhibitors (ICIs) for solid tumors had significantly improved overall survival. This type of therapy has not been evaluated well in acute myeloid leukemia (AML), and basic information on immune checkpoint (IC) expression levels for comprehensively evaluating the prognosis of patients with AML is lacking. The prognostic value of ICs in AML patients was explored by using RNA-seq and mutant data of 176 AML patients from the Cancer Genome Atlas (TCGA) database and further validated the finding using bone marrow (BM) samples from 62 patients with de novo AML from our department by quantitative real-time PCR. Both TCGA data and validation results indicated that high expression of PD-1, PD-L1, and PD-L2 was associated with poor overall survival (OS) in AML patients. In addition, increased co-expression of PD-1 and CTLA-4 (3-year OS: 30% vs 0% (TGCA data), 57% vs 31% (validation group), respectively) or PD-L2 and CTLA-4 (3-year OS: 20% vs 0% (TGCA data), 57% vs 33% (validation group), respectively) correlated with poor AML OS (P < 0.05). Moreover, co-expression of PD-1/PD-L1, PD-1/PD-L1/PD-L2, and PD-1/LAG-3 correlated with poor OS in AML patients with FLT3mut, RUNX1mut, and TET2mut, respectively (P < 0.05). High expression of ICs in the BM leukemia cells of AML patients correlated with poor OS. Co-expressions of PD-1/CTLA-4, PD-L2/CTLA-4, PD-1/PD-L1, PD-1/PD-L1/PD-L2, and PD-1/LAG-3 might be used as novel immune predictors for patient OS in AML, and might guide the best choice for precision immune checkpoint blockade in the future.

The KIR2DL family serves as prognostic biomarkers and correlates with immune infiltrates in acute myeloid leukaemia

A combined immune and exosome-related risk signature as prognostic biomakers in acute myeloid leukemia

KIR 2D (L1, L3, L4, S4) and KIR 3DL1 Protein Expression in Non-Small Cell Lung Cancer

Identification of Molecular and Immune Prognostic Classifiers of Acute Myeloid Leukemia

Identification of Prognosis-Related Genes of Acute Myeloid Leukemia

Identification of Potential Novel Prognosis-Related Genes Through Transcriptome Sequencing, Bioinformatics Analysis, and Clinical Validation in Acute Myeloid Leukemia

Key immune-related gene ITGB2 as a prognostic signature for acute myeloid leukemia

Construction of an Immune-Related Prognostic Signature and lncRNA‒miRNA–mRNA ceRNA Network in Acute Myeloid Leukaemia

3103 – OPTIMAL COMBINATION OF IMMUNE CHECKPOINTS PREDICTS ADVERSE OUTCOMES IN PATIENTS WITH ACUTE MYELOID LEUKEMIA

An Immunogenic Cell Death-Based Risk model Predicts Prognosis and Indicates Immune Infiltration Landscape in Acute Myeloid Leukemia

DOK2 Has Prognostic and Immunologic Significance in Adults with Acute Myeloid Leukemia: A Novel Immune-Related Therapeutic Target

Identification of prognostic genes in the acute myeloid leukemia immune microenvironment based on TCGA data analysis

Gene coexpression network analysis revealed biomarkers correlated with blast cells and survival in acute myeloid leukemia

High Expression of LOC541471, GDAP1, SOD1, and STK25 is Associated with Poor Overall Survival of Patients with Acute Myeloid Leukemia.

Expression Patterns of Immune Checkpoints in Acute Myeloid Leukemia

HCK is a Potential Prognostic Biomarker that Correlates with Immune Cell Infiltration in Acute Myeloid Leukemia

Immune‐related gene signature predicts clinical outcomes and immunotherapy response in acute myeloid leukemia

FLT3LG and IFITM3P6 Consolidate T Cell Activity in the Bone Marrow Microenvironment and Are Prognostic Factors in Acute Myelocytic Leukemia

Novel Prognostic Genes and Subclasses of Acute Myeloid Leukemia Revealed by Survival Analysis of Gene Expression Data.

An immune-related gene prognostic index for acute myeloid leukemia associated with regulatory T cells infiltration

Immune‐relatedlncRNAs Can Predict the Prognosis of Acute Myeloid Leukemia